Anti-Human 4-1BB Recombinant Antibody (TAB-179) (CAT#: TAB-179)

Reithofer, Manuel, et al. "4-1BB costimulation promotes bystander activation of human CD8 T cells." European Journal of Immunology 51.3 (2021): 721-733. https://doi.org/10.1002/eji.202048762

This study explores the impact of 4-1BB costimulation on human CD8 T cells, particularly focusing on bystander activation. The researchers used engineered antigen-presenting cells (eAPCs) expressing viral epitopes and costimulatory ligands to study how different costimulatory signals affect CD8 T cell responses. They found that while CD28 costimulation enhances antigen-specific CD8 T cell responses, 4-1BB costimulation, either through 4-1BB ligand (4-1BBL) or the agonist antibody urelumab, induces significant bystander proliferation of CD8 T cells and expansion of NK cells. This bystander activation is independent of the presented antigens and is characterized by increased cytokine production and cytotoxic activity.
Creative Biolabs contributed significantly to this research by providing the 4-1BB agonist antibody urelumab (Cat# TAB-179). This antibody was crucial for experiments investigating the effects of 4-1BB costimulation on CD8 T cells and NK cells. The use of urelumab enabled the researchers to demonstrate the unique ability of 4-1BB signals to promote bystander activation, thereby advancing the understanding of how 4-1BB costimulation can be harnessed in cancer immunotherapy while also highlighting potential off-target effects that need to be managed.

Upadhyaya, Punit, et al. "Anticancer immunity induced by a synthetic tumor-targeted CD137 agonist." Journal for immunotherapy of cancer 9.1 (2021). https://doi.org/10.1136/jitc-2020-001762

This study investigates the development and efficacy of synthetic tumor-targeted CD137 agonists (TICAs) in inducing anticancer immunity. By using constrained bicyclic peptides (Bicycles) to create TICAs that link tumor antigens (like EphA2) with costimulatory receptors (such as CD137), the researchers were able to selectively activate these receptors in the presence of tumor cells. The study demonstrated that the EphA2/CD137 TICA (BCY12491) efficiently stimulated human peripheral blood mononuclear cells and resulted in significant tumor regression in mouse models. This approach highlights the potential of TICAs to provide effective and targeted cancer immunotherapy with a wide therapeutic index.
Creative Biolabs contributed to this research by supplying the anti-CD137 monoclonal antibody urelumab (Cat# TAB-179). This antibody was crucial for the experiments that investigated the effects of 4-1BB (CD137) costimulation on immune cells. The provision of this key reagent allowed researchers to demonstrate the unique capabilities of TICAs in promoting targeted tumor immunity, thereby supporting the development of new therapeutic strategies in cancer treatment.